2019
DOI: 10.3389/fmicb.2019.01301
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Paracoccidioidomycosis (PCM) is the most prevalent endemic mycosis in Latin America. The disease is caused by fungi of the genus Paracoccidioides and mainly affects low-income rural workers after inhalation of fungal conidia suspended in the air. The current arsenal of chemotherapeutic agents requires long-term administration protocols. In addition, chemotherapy is related to a significantly increased frequency of disease relapse, high toxicity, and incomplete elimination of the fungus. … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
11
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 11 publications
(11 citation statements)
references
References 42 publications
0
11
0
Order By: Relevance
“…We have previously developed an in silico target-based chemogenomics drug repurposing workflow ( 14 ), which led us to identify approved drugs with confirmed activity against the P. falciparum apicoplast ( 15 ), multiple life cycle stages of Schistosoma mansoni ( 16 , 17 ), paracoccidioidomycosis ( 18 ), Schistosoma sp. protein kinases ( 19 ), and Leishmania sp.…”
Section: Introductionmentioning
confidence: 99%
“…We have previously developed an in silico target-based chemogenomics drug repurposing workflow ( 14 ), which led us to identify approved drugs with confirmed activity against the P. falciparum apicoplast ( 15 ), multiple life cycle stages of Schistosoma mansoni ( 16 , 17 ), paracoccidioidomycosis ( 18 ), Schistosoma sp. protein kinases ( 19 ), and Leishmania sp.…”
Section: Introductionmentioning
confidence: 99%
“…Oliveira et al [ 169 ] developed computational drug repurposing—chemo-genomics—to identify anti-PCM activity drugs. The goal of chemo-genomics is to establish the molecular relationships of ligands and targets using genome data [ 170 ], within the concept that “similar targets have similar ligands” [ 171 ].…”
Section: Search For New Therapeutic Options—a Journeymentioning
confidence: 99%
“…The old-drugs that have been repositioned belong to antineoplastic (vistusertib and BGT-226) and azole compounds (bifonazole, luliconazole, butoconazole and sertaconazole). These compounds presented significant antifungal activity [ 169 ].…”
Section: Search For New Therapeutic Options—a Journeymentioning
confidence: 99%
“…Each repurposed drug identified was then searched further in PubMed with the search terms “fungi [and] antifungal [and] repurposed drug name (individual)” to provide a comprehensive antifungal spectrum. Articles relevant to the new antifungal drug development are summarized in Table S1 ( Supplementary Materials ) [ 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 ,…”
Section: Drug Repurposing Approachesmentioning
confidence: 99%
“…Noteworthy is the repurposing study performed by de Oliveira et al [ 15 ] targeting the saprobic/dimorphic Paracoccidioides species, a causative agent of the systemic mycosis paracoccidioidomycosis, which adopted three additional steps: (a) identification of “orthologs” in different isolates of the target pathogen, (b) identification of “homologs” in the drug–target databases, and (c) selection of essential targets in the model fungus Saccharomyces cerevisiae system. The study compiled proteins of three Paracoccidioides species ( P. lutzii , P. americana , and P. brasiliensis ) via the Broad Institute Fungal Genomics Database, followed by the identification of orthologs in Paracoccidioides species.…”
Section: Antifungal Drug Repurposing: Current Measuresmentioning
confidence: 99%